CETN3

Across TCGA pan-cancer cohorts, CETN3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CETN3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CETN3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CETN3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where CETN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	7	view →
HNSC	DFS	Quartile	II,III,IV	0.884	1.000	.013	6	view →
LSCC	OS	Tertile	All	0.944	0.806	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CETN3–CCRCC (DFS)

Open the CCRCC breakdown →